Myron Kaplan Net Worth

The estimated Net Worth of Myron Kaplan is at least $1.35 million dollars as of 18 May 2023. Mr. Kaplan owns over 6,000 units of CorMedix Inc stock worth over $1,147,295 and over the last 9 years he sold CRMD stock worth over $0. In addition, he makes $206,050 as Independent Chairman of the Board at CorMedix Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kaplan CRMD stock SEC Form 4 insiders trading

Myron has made over 20 trades of the CorMedix Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of CRMD stock worth $27,240 on 18 May 2023.

The largest trade he's ever made was buying 104,166 units of CorMedix Inc stock on 12 December 2017 worth over $50,000. On average, Myron trades about 16,452 units every 77 days since 2016. As of 18 May 2023 he still owns at least 166,034 units of CorMedix Inc stock.

You can see the complete history of Mr. Kaplan stock trades at the bottom of the page.

Myron Kaplan biography

Myron M. Kaplan J.D., is an Independent Chairman of the Board of the Company. He is a founding partner of Kleinberg, Kaplan, Wolff & Cohen, P.C., a New York City general practice law firm, where he has practiced corporate and securities law for more than forty years. In 2012, Mr. Kaplan became a trustee of the Lehman Brothers Plan Holding Trust. Previously, he served as a member of the board of directors of SAirGroup Finance (USA) Inc., a subsidiary of SAirGroup that had publicly issued debt securities, Trans World Airlines, Inc. and Kitty Hawk, Inc. Among his business and civic involvements, Mr. Kaplan currently serves on the boards of directors of a number of private companies and has been active for many years on the boards of trustees and various board committees of The Children’s Museum of Manhattan and JBI International (formerly The Jewish Braille Institute of America). Mr. Kaplan graduated from Columbia College and holds a Juris Doctor from Harvard Law School. Among other experience, qualifications, attributes and skills, Mr. Kaplan’s experience in a broad range of corporate and securities matters and service as a director of public companies led to the conclusion of our Board that he should serve as a director of our Company in light of our business and structure.

What is the salary of Myron Kaplan?

As the Independent Chairman of the Board of CorMedix Inc, the total compensation of Myron Kaplan at CorMedix Inc is $206,050. There are 9 executives at CorMedix Inc getting paid more, with Khoso Baluch having the highest compensation of $1,795,830.

How old is Myron Kaplan?

Myron Kaplan is 73, he's been the Independent Chairman of the Board of CorMedix Inc since 2017. There are 2 older and 11 younger executives at CorMedix Inc. The oldest executive at CorMedix Inc is John L. Armstrong Jr., 76, who is the Exec. VP for Technical Operations.

What's Myron Kaplan's mailing address?

Myron's mailing address filed with the SEC is C/O CORMEDIX INC.,, 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS, NJ, 07922.

Insiders trading at CorMedix Inc

Over the last 15 years, insiders at CorMedix Inc have traded over $693,980 worth of CorMedix Inc stock and bought 2,651,866 units worth $3,532,566 . The most active insiders traders include Mehmood Khan, Gary A. Gelbfish et Brian Lenz. On average, CorMedix Inc executives and independent directors trade stock every 30 days with the average trade being worth of $199,105. The most recent stock trade was executed by Joseph Todisco on 13 March 2024, trading 13,561 units of CRMD stock currently worth $50,718.

What does CorMedix Inc do?

cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.

Complete history of Mr. Kaplan stock trades at CorMedix Inc

CorMedix Inc executives and stock owners

CorMedix Inc executives and other stock owners filed with the SEC include:

• Khoso Baluch,
  Chief Executive Officer, Interim Principal Accounting Officer, Director
• Phoebe Mounts,
  Executive Vice President, General Counsel, Head of Regulatory, Compliance and Legal
• Elizabeth Masson,
  Executive Vice President - Head of Clinical Operations
• Khoso Baluch,
  CEO & Director
• Dr. Phoebe Mounts Esq.,
  Exec. VP, Gen. Counsel, Sec. and Head of Regulatory, Compliance & Legal
• John Armstrong,
  Executive Vice President - Technical Operations
• Elizabeth Masson-Hurlburt,
  Exec. VP & Head of Clinical Operations
• John L. Armstrong Jr.,
  Exec. VP for Technical Operations
• Alan Dunton,
  Independent Director
• Myron Kaplan,
  Independent Chairman of the Board
• Steven Lefkowitz,
  Independent Director
• Janet Dillione,
  Independent Director
• Gregory Duncan,
  Director
• Paulo Costa,
  Director
• Matthew David,
  Chief Financial Officer, Executive Vice President
• Thomas Nusbickel,
  Exec. VP & Chief Commercial Officer
• Dr. Paul Chew M.D.,
  Acting Chief Medical Officer
• Dr. Paul Chew,
  Acting Chief Medical Officer
• Dr. Matthew T. David M.D.,
  Exec. VP & CFO
• Judith R Abrams,
  Chief Medical Officer
• Robert W. Cook,
  Chief Financial Officer
• Taunia Markvicka,
  Director
• Antony Pfaffle,
  Director
• Randy Milby,
  Chief Operating Officer
• Cora M Tellez,
  Director
• Mehmood Khan,
  
• Michael W George,
  Director
• Gary A. Gelbfish,
  Director
• James Lefkowitz,
  Director
• Bami Bastani,
  Director
• Timothy M Hofer,
  Secretary
• Mark T. Houser,
  Chief Medical Officer
• John C. Houghton,
  President and CEO
• Mark A. Klausner,
  Chief Medical Officer
• Russell H Ellison,
  Director
• Robert A Stewart,
  
• Matthew Duffy,
  Director
• Harry O'grady,
  Chief Financial Officer
• Richard Cohen,
  Director
• Development Inc Pharmabio,
  10% owner
• Brian Lenz,
  Chief Financial Officer
• Thomas Nusbickel,
  EVP, Chief Commercial Officer
• Joseph Todisco,
  Chief Executive Officer
• Kaufman Beth Zelnick,
  Chief Legal Officer
• Erin Mistry,
  Chief Commercial Officer